TP53 and acute myeloid leukemia: Median OS for TP53 wild-type patients was not yet reached, with a median PFS of 13.3 months (95% CI, 8.6-not reached), while in the case of TP53-mutated AML, median PFS was 5.1 months (95% CI, 1.8-not reached) with median OS of 9.5 months (95% CI, 1.8-not reached), respectively.